{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:11:32Z","timestamp":1793085092059,"version":"4.5.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003793","name":"Swedish Heart Lung Foundation","doi-asserted-by":"publisher","award":["2021-0275"],"award-info":[{"award-number":["2021-0275"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Swedish Heart Lung Foundation","doi-asserted-by":"publisher","award":["2024-0419"],"award-info":[{"award-number":["2024-0419"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region Stockholm","award":["RS 2020-0314"],"award-info":[{"award-number":["RS 2020-0314"]}],"id":[{"id":"https:\/\/ror.org\/02zrae794","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Region Stockholm","award":["RS 2022-0674"],"award-info":[{"award-number":["RS 2022-0674"]}],"id":[{"id":"https:\/\/ror.org\/02zrae794","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Invasive management and intensive antithrombotic regimens have decreased ischemic risk after myocardial infarction (MI) at the cost of more bleeding. Of particular concern is upper gastrointestinal bleeding (UGIB), which is both common and preventable, yet not well characterized over time. We aimed to describe trends of UGIB hospitalization in relation to other bleeding and ischaemic outcomes and explore associated clinical factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We included patients with acute MI who were enrolled in the SWEDEHEART registry, discharged alive on antithrombotic treatment between 1999 and 2020. Patients were followed for hospitalization for adverse events at 1 year. Trends were analysed in 2-year intervals for the overall cohort and subgroups. Standardized event rates for UGIB were calculated to assess the association of changes in demographics, comorbidities, in-hospital procedures, and pharmacotherapy. Bleeding hospitalizations increased from 2.4% to 4.5%, peaking at 4.7% in 2013\u201314, while 1 year major adverse cardiovascular and cerebral events decreased from 20.1% to 9.4%. The gastrointestinal tract was the most common bleeding site across all time intervals, with the majority of cases being UGIBs. Percutaneous coronary intervention, dual antiplatelet therapy, potent antiplatelet agents, and direct oral anticoagulants increased over time. Standardized event rates for UGIB suggest that changes in incidence were associated with evolving management strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Bleeding hospitalizations after MI increased until 2013\u201314, with UGIB the most common source, while ischaemic outcomes declined. These opposing trends were associated with the adoption of invasive management and intensified antithrombotic therapy. Routine tailoring of antithrombotic intensity and systematic gastroprotective measures should be considered as part of post-MI care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag508","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:30:37Z","timestamp":1790425837000},"source":"Crossref","is-referenced-by-count":1,"title":["Long-term trends in upper gastrointestinal bleeding and ischaemic outcomes after myocardial infarction"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2127-070X","authenticated-orcid":false,"given":"Jonatan","family":"W\u00e4rme","sequence":"first","affiliation":[{"name":"Department of Clinical Science and Education Sodersjukhuset, Karolinska Institutet , Sjukhusbacken 10, 118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3775-0839","authenticated-orcid":false,"given":"Moa","family":"Simonsson","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4413-9736","authenticated-orcid":false,"given":"Stefan","family":"James","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center , Uppsala University, Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1718-7820","authenticated-orcid":false,"given":"Lars","family":"Lindhagen","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center , Uppsala University, Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-5766","authenticated-orcid":false,"given":"David","family":"Erlinge","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Lund, Cardiology Unit, Lund University , Lund ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5846-345X","authenticated-orcid":false,"given":"Ole","family":"Fr\u00f6bert","sequence":"additional","affiliation":[{"name":"Faculty of Health, Department of Cardiology, \u00d6rebro University , \u00d6rebro ,","place":["Sweden"]},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Aarhus ,","place":["Denmark"]},{"name":"Steno Diabetes Center Aarhus, Aarhus University Hospital , Aarhus ,","place":["Denmark"]},{"name":"Department of Clinical Pharmacology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1415-7178","authenticated-orcid":false,"given":"Joakim","family":"Alfredsson","sequence":"additional","affiliation":[{"name":"Department of Health, Medicine and Caring Sciences, Linkoping University , Linkoping ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0372-6272","authenticated-orcid":false,"given":"Per","family":"Svensson","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education Sodersjukhuset, Karolinska Institutet , Sjukhusbacken 10, 118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-379X","authenticated-orcid":false,"given":"Tomas","family":"Jernberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-895X","authenticated-orcid":false,"given":"Robin","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education Sodersjukhuset, Karolinska Institutet , Sjukhusbacken 10, 118 83 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"2026102612351051500_zwag508-B1","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1080\/14740338.2019.1680637","article-title":"Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms","volume":"18","author":"Buccheri","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"2026102612351051500_zwag508-B2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/eurheartj\/ehz593","article-title":"Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDEHEART registry","volume":"41","author":"Simonsson","year":"2020","journal-title":"Eur Heart J"},{"key":"2026102612351051500_zwag508-B3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023337","article-title":"Incidence and prognostic impact of post discharge bleeding post acute coronary syndrome within an outpatient setting: a systematic review","volume":"9","author":"Ismail","year":"2019","journal-title":"BMJ Open"},{"key":"2026102612351051500_zwag508-B4","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes","volume":"85","author":"Rao","year":"2025","journal-title":"JACC"},{"key":"2026102612351051500_zwag508-B5","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102612351051500_zwag508-B6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.21037\/atm.2017.06.65","article-title":"Direct oral anticoagulants: analysis of worldwide use and popularity using google trends","volume":"5","author":"Lippi","year":"2017","journal-title":"Ann Transl Med"},{"key":"2026102612351051500_zwag508-B7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2026102612351051500_zwag508-B8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s10557-021-07211-0","article-title":"Review article: gastrointestinal bleeding risk with direct oral anticoagulants","volume":"36","author":"Benamouzig","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026102612351051500_zwag508-B9","doi-asserted-by":"crossref","first-page":"e001645","DOI":"10.1161\/CIRCINTERVENTIONS.114.001645","article-title":"Access and non\u2013access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and Major adverse cardiovascular events","volume":"8","author":"Kwok","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"2026102612351051500_zwag508-B10","first-page":"804","article-title":"Trade-off of myocardial infarction vs. Bleeding types on mortality after acute coronary syndrome: lessons from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"2026102612351051500_zwag508-B11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacc.2020.05.031","article-title":"Post-discharge bleeding and mortality following acute coronary syndromes with or without PCI","volume":"76","author":"Marquis-Gravel","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026102612351051500_zwag508-B12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2026102612351051500_zwag508-B13","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"2026102612351051500_zwag508-B14","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"2026102612351051500_zwag508-B15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ahj.2025.03.014","article-title":"HELicobacter Pylori screening to prevent gastrointestinal bleeding in patients with acute myocardial infarction (HELP-MI SWEDEHEART) - design and rationale of a cluster randomized, crossover, registry-based clinical trial","volume":"286","author":"Hofmann","year":"2025","journal-title":"Am Heart J"},{"key":"2026102612351051500_zwag508-B16","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jama.2025.15047","article-title":"Helicobacter pylori screening after acute myocardial infarction: the cluster randomized crossover HELP-MI SWEDEHEART trial","volume":"334","author":"Hofmann","year":"2025","journal-title":"JAMA"},{"key":"2026102612351051500_zwag508-B17","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/hrt.2010.198804","article-title":"The Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART)","volume":"96","author":"Jernberg","year":"2010","journal-title":"Heart"},{"key":"2026102612351051500_zwag508-B18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ahj.2025.04.028","article-title":"Data quality assessment in the SWEDEHEART registry: insights from serial audits on completeness and accuracy","volume":"288","author":"Leosdottir","year":"2025","journal-title":"Am Heart J"},{"key":"2026102612351051500_zwag508-B19","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"2026102612351051500_zwag508-B20","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026102612351051500_zwag508-B21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"2026102612351051500_zwag508-B22","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2026102612351051500_zwag508-B23","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2026102612351051500_zwag508-B24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.116.003476","article-title":"Contemporary trends in oral anticoagulant prescription in atrial fibrillation patients at low to moderate risk of stroke after guideline-recommended change in use of the CHADS2 to the CHA2DS2-VASc score for thromboembolic risk assessment: analysis from the national cardiovascular data registry\u2019s outpatient practice innovation and clinical excellence atrial fibrillation registry","volume":"10","author":"Katz","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026102612351051500_zwag508-B25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.20030","article-title":"Association of ischemic and bleeding events with mortality among patients in Sweden with recent acute myocardial infarction receiving antithrombotic therapy","volume":"5","author":"Simonsson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026102612351051500_zwag508-B26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013679","article-title":"Bleeding after hospital discharge following acute coronary syndrome: incidence, types, timing, and predictors","volume":"8","author":"Ismail","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026102612351051500_zwag508-B27","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003519","article-title":"Postdischarge bleeding after percutaneous coronary intervention and subsequent mortality and myocardial infarction: insights from the HMO research network-stent registry","volume":"9","author":"Valle","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"2026102612351051500_zwag508-B28","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1001\/jama.2018.8194","article-title":"Annual risk of Major bleeding among persons without cardiovascular disease not receiving antiplatelet therapy","volume":"319","author":"Selak","year":"2018","journal-title":"JAMA"},{"key":"2026102612351051500_zwag508-B29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jacc.2021.10.028","article-title":"Magnetically controlled capsule endoscopy for assessment of antiplatelet therapy-induced gastrointestinal injury","volume":"79","author":"Han","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026102612351051500_zwag508-B30","doi-asserted-by":"crossref","first-page":"101610","DOI":"10.1016\/j.bpg.2019.04.003","article-title":"Changing epidemiology and etiology of upper and lower gastrointestinal bleeding","volume":"42\u201343","author":"Oakland","year":"2019","journal-title":"Best Prac Res Clin Gastroenterol"},{"key":"2026102612351051500_zwag508-B31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.thromres.2023.10.013","article-title":"Gastrointestinal bleeding with direct oral anticoagulants in patients with atrial fibrillation and anaemia","volume":"232","author":"Al-Hussainy","year":"2023","journal-title":"Thromb Res"},{"key":"2026102612351051500_zwag508-B32","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cgh.2022.06.033","article-title":"Warfarin is associated with higher rates of upper but not lower gastrointestinal bleeding compared with direct oral anticoagulants: a population-based propensity-weighted cohort study","volume":"21","author":"Ingason","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026102612351051500_zwag508-B33","doi-asserted-by":"crossref","first-page":"zwaf300","DOI":"10.1093\/eurjpc\/zwaf300","article-title":"Risk factors associated with gastrointestinal bleeding in patients with cardiovascular disease (INTERBLEED): a case control study","author":"Bosch","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026102612351051500_zwag508-B34","doi-asserted-by":"crossref","first-page":"5448587","DOI":"10.1155\/2024\/5448587","article-title":"Use of antidepressant and anxiolytic drugs in scandinavian countries between 2006 and 2021: a prescription database study","volume":"2024","author":"Bojani\u0107","year":"2024","journal-title":"Depress Anxiety"},{"key":"2026102612351051500_zwag508-B35","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0049-3848(19)30362-7","article-title":"Antidepressants: bleeding or thrombosis?","volume":"181","author":"Hoirisch-Clapauch","year":"2019","journal-title":"Thromb Res"},{"key":"2026102612351051500_zwag508-B36","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.gastro.2026.02.028","article-title":"Cardiovascular outcomes following Major gastrointestinal bleeding in patients with Pre-existing cardiovascular disease: the INTERBLEED international prospective cohort study","volume":"171","author":"Forbes","year":"2026","journal-title":"Gastroenterology"},{"key":"2026102612351051500_zwag508-B37","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials","volume":"44","author":"Costa","year":"2023","journal-title":"Eur Heart J"},{"key":"2026102612351051500_zwag508-B38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026102612351051500_zwag508-B39","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.cgh.2014.11.007","article-title":"Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants","volume":"13","author":"Lanas","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026102612351051500_zwag508-B40","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"2026102612351051500_zwag508-B41","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1160\/TH16-05-0400","article-title":"Usefulness of health registers for detection of bleeding events in outcome studies","volume":"116","author":"Friberg","year":"2016","journal-title":"Thromb Haemost"},{"key":"2026102612351051500_zwag508-B42","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2013.02.040","article-title":"Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding","volume":"144","author":"Crooks","year":"2013","journal-title":"Gastroenterology"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag508\/71403485\/zwag508.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag508\/71403485\/zwag508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:35:24Z","timestamp":1793032524000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag508\/8836694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":42,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag508","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"article-number":"zwag508"}}